Avtor/Urednik		Prignano, F; Moretti, S; Carli, P; Giannotti, B
Naslov		What's new in malignant melanoma - treatment
Tip		članek
Vir		Acta Dermatovenerol Alp Pannon Adriat
Vol. in št.		Letnik 4, št. 4
Leto izdaje		1995
Obseg		str. 175-8
Jezik		eng
Abstrakt		The authors discuss biological markers which could make us better understand the function of biological response modifiers (BRMs) and their efficacy in the advanced melanoma treatment. The demonstation, that BRMs, in vitro, inhibit the growth of melanoma cell lines and that they modulate the expression of melanoma associated antigens (MAA) justify their therapeutic application. While the results obtained with chemotherapeuthical substances - alone or in combination - are substantially not very different from the past ones, but interesting progressions are coming from the active immunotherapy. The so called "adoptive immunotherapy" made of a combination of intratumoral T lymphocytes and interleukin 2, is feasible only for a fraction of patients.
Deskriptorji		MELANOMA IMMUNOTHERAPY